Supernus Up on Report of Progress With ADHD Treatment
Supernus Up on Report of Progress With ADHD Treatment Supernus said that a Phase 3 trial met the primary endpoint ... compared to placebo in improving the symptoms of ADHD. Author: Supernus Pharmaceuticals ( SUPN) - Get Report shares jumped on Wednesday after the drugmaker focused on the central nervous system reported progress in a Phase 3 study of an attention-deficit-hyperactivity-disorder drug. Supernus recently traded at $26.70, up 19%. The stock remains off 2% year to date. “At a ...
Jack Khattar Drug Administration Supernus Pharmaceuticals Clinical Global Impression Illness Scale Complete Response Letter
Source: thestreet.com